InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: None

Thursday, 09/21/2017 3:01:31 PM

Thursday, September 21, 2017 3:01:31 PM

Post# of 346046
Xencor at SITC

Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation

Gregory Moore1, Michael Hedvat1, Matthew Bernett1, Christine Bonzon1, Rajat Varma1, Suzanne Schubbert1, Sung-Hyung Lee1, Kendra Avery1, Rumana Rashid1, Alex Nisthal1, Liz Bogaert1, Irene Leung1, Seung Chu1, Umesh Muchhal1, John Desjarlais1

1Xencor, Inc., Monrovia, CA, USA

Antibody | Checkpoint blockade | Costimulation | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

So Xencor playing in same field as PPHM.... Stafford will find out the value of the IP.... he has resources at his disposal...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News